INTERVENTION 1:	Intervention	0
Afatinib Mono	Intervention	1
afatinib	CHEBI:61390	0-8
Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.	Intervention	2
afatinib	CHEBI:61390	0-8
day	UO:0000033	66-69
INTERVENTION 2:	Intervention	3
Afatinib+Vino	Intervention	4
Afatinib 40 mg per day administered orally, continuous treatment, in combination with weekly Vinorelbine 25 mg/mÂ² administered intravenously on days 1, 8, 15 in a 3-weekly course.	Intervention	5
afatinib	CHEBI:61390	0-8
day	UO:0000033	19-22
day	UO:0000033	144-147
vinorelbine	CHEBI:480999	93-104
Inclusion criteria:	Eligibility	0
patients with HER2 positive breast cancer with a documented central nervous system (CNS) recurrence/progression (by imaging) during or after a HER2 inhibitor (Trastuzumab and/or Lapatinib) based therapy (no leptomeningeal carcinomatosis as the only site of CNS metastases)	Eligibility	1
breast cancer	DOID:1612	28-41
central nervous system	UBERON:0001017	60-82
inhibitor	CHEBI:35222	148-157
lapatinib	CHEBI:49603	178-187
site	BFO:0000029	249-253
at least one measurable and progressive lesion in the brain (=10 mm on T1-weighted, gadolinium-enhanced Magnetic Resonance Imaging). Measurable or non measurable extracranial metastases allowed.	Eligibility	2
progressive	HP:0003676	28-39
brain	UBERON:0000955	54-59
previous treatment with HER2 inhibitors to be discontinued prior to first study treatment administration (at least 14 days for trastuzumab and other antibodies, at least 7 days for lapatinib).	Eligibility	3
lapatinib	CHEBI:49603	181-190
previous chemotherapy and hormonal therapy (adjuvant and metastatic regimens) allowed, but chemotherapy must have been discontinued at least 14 days and hormonal therapy at least 7 days prior to first study treatment administration.	Eligibility	4
adjuvant	CHEBI:60809	44-52
Patients must have recovered to baseline condition or to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade = 1 from any acute CTCAE v. 3.0 grade =2 side effects of previous treatments.	Eligibility	5
condition	PDRO:0000129	41-50
acute	HP:0011009,PATO:0000389	143-148
prior surgery, whole brain radiotherapy or stereotactic radiosurgery allowed provided that there is unequivocal evidence of one or more new and/or progressive brain metastases after completion of whole brain radiotherapy or stereotactic radiosurgery.	Eligibility	6
surgery	OAE:0000067	6-13
surgery	OAE:0000067	61-68
surgery	OAE:0000067	242-249
brain	UBERON:0000955	21-26
brain	UBERON:0000955	159-164
brain	UBERON:0000955	202-207
radiotherapy	OAE:0000235	27-39
radiotherapy	OAE:0000235	208-220
progressive	HP:0003676	147-158
Exclusion criteria:	Eligibility	7
Prior treatment with HER2- tyrosine kinase inhibitor other than lapatinib	Eligibility	8
tyrosine kinase inhibitor	CHEBI:38637	27-52
lapatinib	CHEBI:49603	64-73
Any other current malignancy or malignancy diagnosed within the past five (5) years (other than bilateral primary breast cancer, metastases to the contralateral breast, non-melanomatous skin cancer and in situ cervical cancer).	Eligibility	9
bilateral	HP:0012832	96-105
breast cancer	DOID:1612	114-127
breast	UBERON:0000310	114-120
breast	UBERON:0000310	161-167
skin cancer	DOID:4159	186-197
cervical cancer	DOID:4362	210-225
Significant chronic or recent acute gastrointestinal disorders with diarrhoea as a major symptom e.g. Crohn's disease, malabsorption or Common Terminology Criteria (CTC) grade =2 diarrhoea of any aetiology.	Eligibility	10
chronic	HP:0011010	12-19
acute	HP:0011009,PATO:0000389	30-35
symptom	OGMS:0000020	89-96
disease	DOID:4,OGMS:0000031	110-117
malabsorption	HP:0002024	119-132
Outcome Measurement:	Results	0
Patient Benefit Rate at 12 Weeks	Results	1
patient	HADO:0000008,OAE:0001817	0-7
rate	BAO:0080019	16-20
Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS), no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1	Results	2
patient	HADO:0000008,OAE:0001817	14-21
patient	HADO:0000008,OAE:0001817	28-35
patient	HADO:0000008,OAE:0001817	56-63
week	UO:0000034	47-51
central nervous system	UBERON:0001017	102-124
disease	DOID:4,OGMS:0000031	131-138
disease	DOID:4,OGMS:0000031	404-411
increase	BAO:0001251	338-346
corticosteroid	CHEBI:50858	350-364
Time frame: 12 weeks from randomisation	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Afatinib Mono	Results	5
afatinib	CHEBI:61390	17-25
Arm/Group Description: Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.	Results	6
afatinib	CHEBI:61390	23-31
day	UO:0000033	89-92
Overall Number of Participants Analyzed: 40	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of participants  30.0        (16.6 to 46.5)	Results	9
Results 2:	Results	10
Arm/Group Title: Afatinib+Vino	Results	11
Arm/Group Description: Afatinib 40 mg per day administered orally, continuous treatment, in combination with weekly Vinorelbine 25 mg/m  administered intravenously on days 1, 8, 15 in a 3-weekly course.	Results	12
afatinib	CHEBI:61390	23-31
day	UO:0000033	42-45
day	UO:0000033	167-170
vinorelbine	CHEBI:480999	116-127
Overall Number of Participants Analyzed: 38	Results	13
Measure Type: Number	Results	14
Unit of Measure: percentage of participants  34.2        (19.6 to 51.4)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 18/40 (45.00%)	Adverse Events	1
Anaemia 0/40 (0.00%)	Adverse Events	2
Febrile neutropenia 0/40 (0.00%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Progressive cerebellar degeneration 0/40 (0.00%)	Adverse Events	4
progressive	HP:0003676	0-11
Vertigo 0/40 (0.00%)	Adverse Events	5
vertigo	HP:0002321	0-7
Diarrhoea 3/40 (7.50%)	Adverse Events	6
Dysphagia 0/40 (0.00%)	Adverse Events	7
dysphagia	HP:0002015	0-9
Enteritis 0/40 (0.00%)	Adverse Events	8
Ileus 0/40 (0.00%)	Adverse Events	9
ileus	HP:0002595,DOID:8440	0-5
Intestinal obstruction 0/40 (0.00%)	Adverse Events	10
intestinal obstruction	HP:0005214,DOID:8437	0-22
Nausea 1/40 (2.50%)	Adverse Events	11
nausea	HP:0002018	0-6
Stomatitis 1/40 (2.50%)	Adverse Events	12
stomatitis	HP:0010280,DOID:9637	0-10
Subileus 0/40 (0.00%)	Adverse Events	13
Vomiting 3/40 (7.50%)	Adverse Events	14
vomiting	HP:0002013	0-8
Adverse Events 2:	Adverse Events	15
Total: 24/37 (64.86%)	Adverse Events	16
Anaemia 1/37 (2.70%)	Adverse Events	17
Febrile neutropenia 3/37 (8.11%)	Adverse Events	18
neutropenia	HP:0001875,DOID:1227	8-19
Progressive cerebellar degeneration 0/37 (0.00%)	Adverse Events	19
progressive	HP:0003676	0-11
Vertigo 0/37 (0.00%)	Adverse Events	20
vertigo	HP:0002321	0-7
Diarrhoea 5/37 (13.51%)	Adverse Events	21
Dysphagia 1/37 (2.70%)	Adverse Events	22
dysphagia	HP:0002015	0-9
Enteritis 1/37 (2.70%)	Adverse Events	23
Ileus 1/37 (2.70%)	Adverse Events	24
ileus	HP:0002595,DOID:8440	0-5
Intestinal obstruction 1/37 (2.70%)	Adverse Events	25
intestinal obstruction	HP:0005214,DOID:8437	0-22
Nausea 0/37 (0.00%)	Adverse Events	26
nausea	HP:0002018	0-6
Stomatitis 1/37 (2.70%)	Adverse Events	27
stomatitis	HP:0010280,DOID:9637	0-10
Subileus 1/37 (2.70%)	Adverse Events	28
Vomiting 2/37 (5.41%)	Adverse Events	29
vomiting	HP:0002013	0-8
